Symbols / ARTV $6.32 +2.27%
ARTV Chart
About
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 155.12M |
| Enterprise Value | 59.14M | Income | -83.86M | Sales | — |
| Book/sh | 4.53 | Cash/sh | 4.37 | Dividend Yield | — |
| Payout | 0.00% | Employees | 104 | IPO | — |
| P/E | — | Forward P/E | -2.55 | PEG | — |
| P/S | — | P/B | 1.40 | P/C | — |
| EV/EBITDA | -0.68 | EV/Sales | — | Quick Ratio | 8.31 |
| Current Ratio | 8.61 | Debt/Eq | 9.95 | LT Debt/Eq | — |
| EPS (ttm) | -1.24 | EPS next Y | -2.48 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-10 16:00 | ROA | -32.97% |
| ROE | -56.55% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 24.54M |
| Shs Float | 4.23M | Short Float | 1.50% | Short Ratio | 0.95 |
| Short Interest | — | 52W High | 7.75 | 52W Low | 1.47 |
| Beta | — | Avg Volume | 200.76K | Volume | 100.50K |
| Target Price | $17.00 | Recom | Strong_buy | Prev Close | $6.18 |
| Price | $6.32 | Change | 2.27% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$17.00
Mean price target
2. Current target
$6.32
Latest analyst target
3. DCF / Fair value
$-36.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.32
Low
$10.00
High
$23.00
Mean
$17.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | reit | Needham | Buy → Buy | $18 |
| 2025-11-12 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-10-17 | main | Wedbush | Outperform → Outperform | $23 |
| 2025-10-17 | reit | Needham | Buy → Buy | $18 |
| 2025-05-15 | main | Needham | Buy → Buy | $18 |
| 2025-04-08 | reit | Needham | Buy → Buy | $23 |
| 2025-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-03-25 | reit | Wedbush | Outperform → Outperform | $18 |
| 2025-03-25 | main | Cantor Fitzgerald | Overweight → Overweight | $20 |
| 2025-03-25 | reit | Needham | Buy → Buy | $23 |
| 2024-12-30 | init | HC Wainwright & Co. | — → Buy | $20 |
| 2024-11-13 | reit | Needham | Buy → Buy | $23 |
| 2024-08-30 | reit | Needham | Buy → Buy | $23 |
| 2024-08-13 | init | Needham | — → Buy | $23 |
| 2024-08-13 | init | Wedbush | — → Outperform | $18 |
| 2024-08-13 | init | Cantor Fitzgerald | — → Overweight | $23 |
| 2024-08-13 | init | TD Cowen | — → Buy | — |
| 2024-08-13 | init | Jefferies | — → Buy | $21 |
- ARTV Stock Price and Chart — NASDAQ:ARTV - TradingView Fri, 06 Feb 2026 08
- $ARTV stock is up 19% today. Here's what we see in our data. - Quiver Quantitative Wed, 11 Mar 2026 14
- Artiva Biotherapeutics Stock: Upcoming Data Presentations In Focus (NASDAQ:ARTV) - Seeking Alpha hu, 15 Jan 2026 08
- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decrease in Short Interest - MarketBeat Sun, 15 Mar 2026 07
- Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy from Jefferies - The Globe and Mail Fri, 13 Mar 2026 13
- Artiva Biotherapeutics (ARTV): Valuation Snapshot Following FDA Fast Track for AlloNK in Refractory Rheumatoid Arthritis - Yahoo Finance Mon, 20 Oct 2025 07
- Artiva Bio president Aslan sells $153k in ARTV stock - Investing.com Fri, 17 Oct 2025 07
- Artiva (NASDAQ: ARTV) reports no CRS/ICANS with AlloNK in 32 patients - Stock Titan Wed, 12 Nov 2025 08
- Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next - TechStock² ue, 16 Dec 2025 08
- Artiva Biotherapeutics' (ARTV) Buy Rating Reiterated at Needham & Company LLC - MarketBeat Wed, 11 Mar 2026 12
- Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance Sun, 14 Dec 2025 08
- Cantor Fitzgerald reiterates Artiva Biotherapeutics stock rating - Investing.com Wed, 11 Mar 2026 12
- Artiva Biotherapeutics Appoints Thad Huston as Chief Financial Officer - The Globe and Mail Wed, 25 Feb 2026 08
- Artiva Biotherapeutics (ARTV) Is Up 113.9% After FDA Fast Track for AlloNK in Refractory RA – Has the Bull Case Changed? - Yahoo Finance Sun, 19 Oct 2025 07
- Aslan Fred sells Artiva Biotherapeutics (ARTV) stock for $21,522 - Investing.com Mon, 17 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 220000 | — | — | Stock Award(Grant) at price 0.00 per share. | HUSTON THAD ALLEN | Chief Financial Officer | — | 2026-03-10 00:00:00 | D |
| 1 | 117300 | — | — | Stock Award(Grant) at price 0.00 per share. | BUSH JENNIFER KINSBRUNER | Chief Operating Officer | — | 2026-02-13 00:00:00 | D |
| 2 | 117300 | — | — | Stock Award(Grant) at price 0.00 per share. | HORAN CHRISTOPHER | Chief Operating Officer | — | 2026-02-13 00:00:00 | D |
| 3 | 366850 | — | — | Stock Award(Grant) at price 0.00 per share. | ASLAN FRED M.D. | Chief Executive Officer | — | 2026-02-13 00:00:00 | D |
| 4 | 46000 | — | — | Stock Award(Grant) at price 0.00 per share. | RAYMON HEATHER | Officer | — | 2026-02-13 00:00:00 | D |
| 5 | 102000 | — | — | Stock Award(Grant) at price 0.00 per share. | BANERJEE SUBHASHIS M.D. | Officer | — | 2026-02-13 00:00:00 | D |
| 6 | 3187 | 10517.0 | — | Sale at price 3.30 per share. | ASLAN FRED M.D. | Chief Executive Officer | — | 2025-12-15 00:00:00 | D |
| 7 | 84877 | — | — | Stock Award(Grant) at price 0.00 per share. | BUSH JENNIFER KINSBRUNER | Chief Operating Officer | — | 2025-12-12 00:00:00 | D |
| 8 | 107156 | — | — | Stock Award(Grant) at price 0.00 per share. | HORAN CHRISTOPHER | Chief Operating Officer | — | 2025-12-12 00:00:00 | D |
| 9 | 869136 | — | — | Stock Award(Grant) at price 0.00 per share. | ASLAN FRED M.D. | Chief Executive Officer | — | 2025-12-12 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.21 | 0.00 |
| NormalizedEBITDA | -64.85M | -28.41M | -58.67M | -71.58M |
| TotalUnusualItems | 3.60M | 707.00K | ||
| TotalUnusualItemsExcludingGoodwill | 3.60M | 707.00K | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -69.19M | -32.77M | -60.98M | -71.83M |
| ReconciledDepreciation | 2.43M | 2.27M | 1.16M | 248.00K |
| EBITDA | -64.85M | -28.41M | -58.67M | -71.58M |
| EBIT | -67.28M | -30.67M | -59.83M | -71.83M |
| NetInterestIncome | -5.35M | -2.54M | -1.29M | 0.00 |
| InterestExpense | 0.00 | |||
| InterestIncome | -5.35M | -2.54M | -1.29M | 0.00 |
| NormalizedIncome | -69.19M | -32.77M | -60.98M | -71.83M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -69.19M | -32.77M | -60.98M | -71.83M |
| TotalExpenses | 67.53M | 64.16M | 64.76M | 55.27M |
| TotalOperatingIncomeAsReported | -67.28M | -30.67M | -59.83M | -53.27M |
| DilutedAverageShares | 11.26M | 23.28M | 9.36M | 9.36M |
| BasicAverageShares | 11.26M | 23.28M | 9.36M | 9.36M |
| DilutedEPS | -5.81 | -1.41 | -6.51 | -7.67 |
| BasicEPS | -5.81 | -1.41 | -6.51 | -7.67 |
| DilutedNIAvailtoComStockholders | -69.19M | -32.77M | -60.98M | -71.83M |
| NetIncomeCommonStockholders | -69.19M | -32.77M | -60.98M | -71.83M |
| NetIncome | -69.19M | -32.77M | -60.98M | -71.83M |
| NetIncomeIncludingNoncontrollingInterests | -69.19M | -32.77M | -60.98M | -71.83M |
| NetIncomeContinuousOperations | -69.19M | -32.77M | -60.98M | -71.83M |
| TaxProvision | 0.00 | 72.00K | 53.00K | |
| PretaxIncome | -69.19M | -32.69M | -60.92M | -71.83M |
| OtherIncomeExpense | 3.44M | 512.00K | 200.00K | -18.55M |
| OtherNonOperatingIncomeExpenses | 3.44M | 512.00K | 200.00K | -18.55M |
| GainOnSaleOfSecurity | 3.60M | 707.00K | ||
| NetNonOperatingInterestIncomeExpense | -5.35M | -2.54M | -1.29M | 0.00 |
| InterestExpenseNonOperating | 0.00 | |||
| InterestIncomeNonOperating | -5.35M | -2.54M | -1.29M | 0.00 |
| OperatingIncome | -67.28M | -30.67M | -59.83M | -53.27M |
| OperatingExpense | 67.53M | 64.16M | 64.76M | 55.27M |
| ResearchAndDevelopment | 50.33M | 50.25M | 43.98M | 42.41M |
| SellingGeneralAndAdministration | 17.20M | 13.91M | 20.78M | 12.86M |
| GeneralAndAdministrativeExpense | 17.20M | 13.91M | 20.78M | 12.86M |
| OtherGandA | 17.20M | 13.91M | 20.78M | 12.86M |
| TotalRevenue | 251.00K | 33.49M | 4.93M | 2.00M |
| OperatingRevenue | 0.00 | 32.92M | 4.93M | 2.00M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 24.29M | 23.28M | 23.28M | 23.28M |
| ShareIssued | 24.29M | 23.28M | 23.28M | 23.28M |
| TotalDebt | 14.35M | 16.91M | 19.45M | 1.74M |
| TangibleBookValue | 186.64M | -162.01M | -140.70M | -88.86M |
| InvestedCapital | 186.64M | -162.01M | -140.70M | -88.86M |
| WorkingCapital | 176.38M | 67.59M | 79.05M | 142.98M |
| NetTangibleAssets | 186.64M | -162.01M | -140.70M | -88.86M |
| CapitalLeaseObligations | 14.35M | 16.91M | 19.45M | 1.74M |
| CommonStockEquity | 186.64M | -162.01M | -140.70M | -88.86M |
| TotalCapitalization | 186.64M | -162.01M | -140.70M | -88.86M |
| TotalEquityGrossMinorityInterest | 186.64M | -162.01M | -140.70M | -88.86M |
| StockholdersEquity | 186.64M | -162.01M | -140.70M | -88.86M |
| GainsLossesNotAffectingRetainedEarnings | -129.00K | 308.00K | 0.00 | |
| OtherEquityAdjustments | -129.00K | 308.00K | ||
| RetainedEarnings | -246.68M | -181.31M | -152.59M | -93.80M |
| AdditionalPaidInCapital | 433.45M | 18.99M | 11.89M | 4.95M |
| CapitalStock | 3.00K | 0.00 | 0.00 | 0.00 |
| CommonStock | 3.00K | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 22.94M | 267.13M | 273.75M | 258.78M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 10.69M | 254.90M | 248.12M | 239.48M |
| OtherNonCurrentLiabilities | 73.00K | 73.00K | 115.00K | 81.00K |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 216.41M | 216.41M | 216.41M |
| DerivativeProductLiabilities | 0.00 | 25.10M | 0.00 | |
| NonCurrentDeferredLiabilities | 0.00 | 15.63M | 21.68M | |
| NonCurrentDeferredRevenue | 0.00 | 15.63M | 21.68M | |
| LongTermDebtAndCapitalLeaseObligation | 10.61M | 13.32M | 15.96M | 1.31M |
| LongTermCapitalLeaseObligation | 10.61M | 13.32M | 15.96M | 1.31M |
| CurrentLiabilities | 12.25M | 12.23M | 25.62M | 19.30M |
| CurrentDeferredLiabilities | 0.00 | 10.89M | 7.29M | |
| CurrentDeferredRevenue | 0.00 | 10.89M | 7.29M | |
| CurrentDebtAndCapitalLeaseObligation | 3.74M | 3.60M | 3.49M | 433.00K |
| CurrentCapitalLeaseObligation | 3.74M | 3.60M | 3.49M | 433.00K |
| PayablesAndAccruedExpenses | 8.51M | 8.63M | 11.25M | 11.58M |
| CurrentAccruedExpenses | 7.39M | 8.02M | 10.15M | 10.13M |
| Payables | 1.12M | 614.00K | 1.10M | 1.44M |
| AccountsPayable | 1.12M | 614.00K | 1.10M | 1.44M |
| TotalAssets | 209.58M | 105.11M | 133.05M | 169.93M |
| TotalNonCurrentAssets | 20.95M | 25.29M | 28.37M | 7.64M |
| OtherNonCurrentAssets | 525.00K | 650.00K | 762.00K | 387.00K |
| NonCurrentDeferredAssets | 3.17M | |||
| NetPPE | 20.43M | 24.64M | 27.61M | 4.08M |
| AccumulatedDepreciation | -5.92M | -3.53M | -1.26M | -333.00K |
| GrossPPE | 26.35M | 28.18M | 28.88M | 4.41M |
| Leases | 410.00K | 390.00K | 283.00K | 43.00K |
| OtherProperties | 24.45M | 26.31M | 27.13M | 3.73M |
| MachineryFurnitureEquipment | 1.49M | 1.48M | 1.47M | 641.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 188.63M | 79.82M | 104.67M | 162.29M |
| OtherCurrentAssets | 3.06M | 1.09M | 1.62M | 896.00K |
| PrepaidAssets | 896.00K | |||
| Receivables | 146.00K | 1.76M | 525.00K | 468.00K |
| OtherReceivables | 146.00K | 117.00K | ||
| DuefromRelatedPartiesCurrent | 0.00 | 607.00K | 0.00 | |
| AccountsReceivable | 0.00 | 1.03M | 525.00K | 468.00K |
| CashCashEquivalentsAndShortTermInvestments | 185.43M | 76.97M | 102.53M | 160.92M |
| OtherShortTermInvestments | 145.19M | 23.47M | 0.00 | |
| CashAndCashEquivalents | 40.23M | 53.50M | 102.53M | 160.92M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -55.67M | -50.69M | -57.13M | -17.03M |
| RepurchaseOfCapitalStock | -4.18M | -12.00K | -5.00K | |
| RepaymentOfDebt | -149.00K | 0.00 | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 166.51M | 0.00 | 154.61M | |
| CapitalExpenditure | -642.00K | -3.26M | -6.30M | -1.72M |
| IncomeTaxPaidSupplementalData | 0.00 | 83.00K | 0.00 | |
| EndCashPosition | 40.49M | 53.76M | 102.78M | 161.17M |
| BeginningCashPosition | 53.76M | 102.78M | 161.17M | 25.44M |
| ChangesInCash | -13.27M | -49.01M | -58.39M | 135.73M |
| FinancingCashFlow | 162.23M | 24.39M | -1.26M | 152.75M |
| CashFlowFromContinuingFinancingActivities | 162.23M | 24.39M | -1.26M | 152.75M |
| NetOtherFinancingCharges | 24.39M | -1.59M | -2.03M | |
| ProceedsFromStockOptionExercised | 51.00K | 10.00K | 332.00K | 175.00K |
| NetPreferredStockIssuance | 154.61M | |||
| PreferredStockIssuance | 154.61M | |||
| NetCommonStockIssuance | 162.32M | -12.00K | -5.00K | 0.00 |
| CommonStockPayments | -4.18M | -12.00K | -5.00K | |
| CommonStockIssuance | 166.51M | 0.00 | 0.00 | |
| NetIssuancePaymentsOfDebt | -149.00K | 0.00 | 0.00 | |
| NetLongTermDebtIssuance | -149.00K | 0.00 | 0.00 | |
| LongTermDebtPayments | -149.00K | 0.00 | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -120.46M | -25.98M | -6.30M | -1.72M |
| CashFlowFromContinuingInvestingActivities | -120.46M | -25.98M | -6.30M | -1.72M |
| NetInvestmentPurchaseAndSale | -119.82M | -22.72M | 0.00 | |
| SaleOfInvestment | 56.35M | 26.80M | 0.00 | |
| PurchaseOfInvestment | -176.17M | -49.52M | 0.00 | |
| NetPPEPurchaseAndSale | -642.00K | -3.26M | -6.30M | -1.72M |
| PurchaseOfPPE | -642.00K | -3.26M | -6.30M | -1.72M |
| OperatingCashFlow | -55.03M | -47.43M | -50.83M | -15.30M |
| CashFlowFromContinuingOperatingActivities | -55.03M | -47.43M | -50.83M | -15.30M |
| ChangeInWorkingCapital | -325.00K | -28.28M | -3.87M | 33.41M |
| ChangeInOtherWorkingCapital | 43.00K | -26.38M | -2.38M | 28.92M |
| ChangeInOtherCurrentLiabilities | 0.00 | 74.00K | ||
| ChangeInOtherCurrentAssets | 125.00K | 139.00K | -121.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | -140.00K | -1.32M | -615.00K | 5.19M |
| ChangeInAccruedExpense | -659.00K | -912.00K | -805.00K | 6.43M |
| ChangeInPayable | 519.00K | -408.00K | 190.00K | -1.24M |
| ChangeInAccountPayable | 519.00K | -408.00K | 190.00K | -1.24M |
| ChangeInPrepaidAssets | -1.97M | 516.00K | -764.00K | -230.00K |
| ChangeInReceivables | 1.61M | -1.23M | -57.00K | -468.00K |
| ChangesInAccountReceivables | 1.03M | -510.00K | -57.00K | -468.00K |
| OtherNonCashItems | 18.55M | |||
| StockBasedCompensation | 6.98M | 7.05M | 6.58M | 4.31M |
| AssetImpairmentCharge | 0.00 | 4.08M | ||
| AmortizationOfSecurities | -2.34M | -456.00K | 0.00 | |
| DepreciationAmortizationDepletion | 2.43M | 2.27M | 1.16M | 248.00K |
| DepreciationAndAmortization | 2.43M | 2.27M | 1.16M | 248.00K |
| OperatingGainsLosses | 3.60M | 707.00K | ||
| GainLossOnInvestmentSecurities | 3.60M | 707.00K | ||
| NetIncomeFromContinuingOperations | -65.37M | -28.72M | -58.79M | -71.83M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ARTV
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|